Tevogen Bio Holdings Inc.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN, NJ, 07059
Mailing Address
15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN, NJ, 07059
Phone
646-807-8832
Fiscal Year End
1231
EIN
981597194
Financial Overview
FY2025
-
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 8-K Current report of material events | February 25, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | December 22, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | December 16, 2025 | View on SEC |
| 4 Insider stock transaction report | December 15, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Successful Phase 1 trial validation for lead product TVGN 489 in high-risk COVID-19 patients.
- Proprietary ExacTcell platform offers a scalable, 'off-the-shelf' alternative to traditional personalized T cell therapies.
Material Events
8-K
Strategy Change
March 4, 2026
High Impact
- Meets Nasdaq's $1.00 minimum share price requirement, preventing delisting.
- Enhances appeal to institutional investors and improves stock liquidity.
8-K
Strategy Change
February 25, 2026
High Impact
- Stockholders approved an expanded 2024 Equity Incentive Plan, increasing shares by 100,000,000 to attract and retain top talent, linking success to the clinical pipeline (TVGN 489).
- Authorization for a reverse stock split (1:25 to 1:85 ratio) aims to boost the stock price above Nasdaq's $1.00 minimum bid, crucial for maintaining its listing.
Insider Trading
SELL
1 insiders
3 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2836)
Kodiak Sciences Inc.
KOD
Biological Products, (No Diagnostic Substances)
BioAtla, Inc.
BCAB
Biological Products, (No Diagnostic Substances)
Cardiff Oncology, Inc.
CRDF
Biological Products, (No Diagnostic Substances)
HALOZYME THERAPEUTICS, INC.
HALO
Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp
ADPT
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.